Biocon Receives Another FDA Setback On Insulin Aspart

Further Complete Response Letter Issued After Inspection Not Scheduled Ahead Of Goal Date

 
• By David Wallace
Sign outside of FDA's headquarters in White Oak, MD
The FDA did not schedule a reinspection ahead of Biocon’s goal date • Source: Alamy

More from Biosimilars

More from Products